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ARTICLE OPEN
Physical activity and risk of comorbidities in patients with
chronic obstructive pulmonary disease: a cohort study
Tsung Yu1,2, Gerben ter Riet3, Milo A. Puhan1 and Anja Frei1
Multi-morbidity is common in patients with chronic obstructive pulmonary disease and low levels of physical activity are
hypothesized to be an important risk factor. The current study aimed to assess the longitudinal association between physical
activity and risk of seven categories of comorbidity in chronic obstructive pulmonary disease patients. The study included 409
patients from primary care practice in the Netherlands and Switzerland. We assessed physical activity using the Longitudinal Ageing
Study Amsterdam Physical Activity Questionnaire at baseline and followed patients for up to 5 years. During follow-up, patients
reported their comorbidities (cardiovascular, neurological, endocrine, musculoskeletal, malignant, and infectious diseases) and
completed the Hospital Anxiety and Depression Scale questionnaire for mental health assessment. We implemented multinomial
logistic regression (an approximation to discrete time survival model using death as a competing risk) for our analysis. Study results
did not suggest a statistically signiﬁcant association of baseline physical activity with the development of seven categories of
comorbidity. However, when we focused on depression and anxiety symptoms, we found that higher levels of physical activity at
baseline were associated with a lower risk for depression (adjusted hazard ratio, 0.85; 0.75–0.95; p = 0.005) and anxiety (adjusted
hazard ratio, 0.89; 0.79–1.00; p = 0.045). In chronic obstructive pulmonary disease patients, those with high physical activity are less
likely to develop depression or anxiety symptoms over time. Increasing physical activity in chronic obstructive pulmonary disease
patients may be an approach for testing to lower the burden from incident depression and anxiety.
npj Primary Care Respiratory Medicine  (2017) 27:36 ; doi:10.1038/s41533-017-0034-x
INTRODUCTION
The clinical manifestations of chronic obstructive pulmonary
disease (COPD) are diverse. Five decades ago, the “pink puffer”
and the “blue bloater” were introduced as a way to show distinct
combinations of clinical manifestations, which included cardio-
vascular comorbidity.1 More recently, researchers have attempted
to identify phenotypes of COPD and also pointed out the
prominent role of comorbidities.2 Comorbidities such as cardio-
vascular diseases, diabetes mellitus, depression, and musculoske-
letal disorders are more prevalent in COPD patients than in sex-
and age-matched healthy individuals.3 Besides reducing patients’
health-related quality of life,4 comorbidities are associated with an
increased risk of all-cause hospital admission and death,5 and they
contribute to more health-care use and cost.6
Low physical activity (PA) is an important feature of COPD
patients and has received much attention in research recently.7–9
Consistent evidence suggests that low PA levels are associated
with death and COPD exacerbations,7 and are hypothesized to be
an important risk factor for multi-morbidity in COPD patients.10–12
Some biological mechanisms have been proposed to explain
these associations. For example, low PA levels may adversely
affect lipid lipoprotein proﬁles, glucose homeostasis, insulin
sensitivity, and inﬂammation status, which together increase the
risk for developing chronic diseases in these patients.13
However, most studies on the association of PA with
comorbidity in COPD were cross-sectional. For instance, Remoortel
and colleagues11 recently demonstrated in a population-based
study that smoking and physical inactivity were strongly
associated with the presence of comorbidity in pre-clinical COPD
patients. Since longitudinal evidence is scarce, the issue of reverse
causation may severely limit the validity of some of these
ﬁndings.7
The aim of the current study was to assess the longitudinal
association of PA with the incidence of comorbidities. We studied
this in a 5-year prospective follow-up study of COPD patients
including seven categories of comorbidity, that is, cardiovascular,
neurological, endocrine, musculoskeletal, mental, malignant, and
infectious diseases.
RESULTS
Description of study subjects
The study recruited 258 patients from the Netherlands and 151
patients from Switzerland, respectively. Baseline characteristics of
patients are shown in Table 1 and more details were reported
previously.14, 15 The median of the Longitudinal Ageing Study
Amsterdam Physical Activity Questionnaire (LAPAQ) score that is
indicative of types of PA and weighted by intensity was 11
(interquartile range 8.5–15). The median number of visits after
which an additional comorbidity was identiﬁed was three
(equivalent to 1.5 years after baseline).
Table 2 shows the prevalence of seven categories of
comorbidity at study baseline.
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Association of PA with incident comorbidities
In Fig. 1 we classiﬁed the patients at every visit into those with 0 or
1 category of comorbidities, those with ≥ 2 categories of
comorbidities, and those who were dead or lost to follow-up. As
expected, the proportion of patients with 0 or 1 comorbidity
decreased over time. During study follow-up, the number of new
cases of cardiovascular diseases was 24, of neurological disorders
24, of endocrine disorders 5, of musculoskeletal disorders 34, of
mental disorders 92, of cancers 13, and of infectious diseases 13.
Overall, the risk of developing any additional comorbidity over
time was 7% lower for a 2.5-point increase in the LAPAQ score at
baseline (unadjusted hazard ratio = 0.93; 95% conﬁdence interval (CI):
0.87–0.99; p = 0.03). The corresponding ﬁgures (unadjusted hazard
ratios) by category of comorbidity were 0.96 (0.80–1.15;
p= 0.63) for cardiovascular diseases, 0.97 (0.80–1.16; p = 0.71) for
neurological disorders, 0.82 (0.54–1.26; p= 0.37) for endocrine
disorders, 0.88 (0.76–1.03; p = 0.12) for musculoskeletal disorders,
0.90 (0.82–0.99; p= 0.04) for mental disorders, 0.80 (0.61–1.03;
p= 0.08) for cancers and 0.86 (0.72–1.04; p= 0.12) for infectious
diseases.
We also computed adjusted hazard ratios for risk of comorbid-
ities overall and by the seven categories, with regard to a 2.5-point
increase in the LAPAQ score (Fig. 2). The adjusted hazard ratios
were 0.95 (95% CI: 0.88–1.01; p = 0.12) for developing an
additional comorbidity, 0.97 (95% CI: 0.80–1.18; p = 0.77) for
cardiovascular diseases, 1.03 (0.85–1.25; p = 0.73) for neurological
disorders, 0.92 (0.60–1.41; p = 0.71) for endocrine disorders, 0.88
(0.74–1.04; p = 0.12) for musculoskeletal disorders, 0.92 (0.83–1.02;
p = 0.13) for mental disorders, 0.86 (0.65–1.13; p = 0.27) for cancers
and 0.85 (0.69–1.03; p = 0.09) for infectious diseases.
We did post hoc analysis on the association of PA with the
incidence of depression and anxiety in particular because the
previous analyses suggested that there may be an association of
PA with mental disorders. Also, compared to other comorbidities,
there were many more cases and thus more power for analysis,
with both depression (79 cases) and anxiety (80 cases). Results
from the competing risk model are shown in Table 3. The adjusted
hazard ratios for depression and anxiety were 0.85 (0.75–0.95; p =
0.005) and 0.89 (0.79–1.00; p = 0.045), respectively.
Results of sensitivity analyses with the average of PA scores over
time as the exposure were similar to results of main analyses,
except that the effect on anxiety became statistically non-
signiﬁcant (e-Appendix).
DISCUSSION
The current study investigated the association of PA with the risk
of seven categories of comorbidity in patients with COPD. Using
data from a 5-year longitudinal study, we found that higher levels
of PA are associated with a lower risk of developing clinically
relevant depression and possibly anxiety symptoms, for which we
considered death as a competing event. However, for the other
comorbidities that were examined here, there was inconclusive to
weak evidence to suggest a statistically signiﬁcant association of
PA with incident risk of comorbidities.
Our study, in line with other previous research,3 found a high
prevalence of comorbidities in patients with COPD. Many
investigations5, 16 quantiﬁed the impact of comorbidities on
patient’s health status and on their risk of death. For example, we
reported previously that comorbidities including depression,
anxiety, and peripheral artery disease had a large impact on
patient’s health status.16 In another study, investigators included
12 comorbidities such as lung cancer, breast cancer, and anxiety
to construct an index that aims to assess the impact of
comorbidities on patient’s risk of death.5 To alleviate the impact
of comorbidities on patient’s health as well as to develop and
optimize treatment strategies for COPD, studying the modiﬁable
Table 1. Baseline characteristics of study patients
Characteristics Number of patients: 409
Nationality
Switzerland, n (%) 151 (37%)
The Netherlands, n (%) 258 (63%)
Sex
Male, n (%) 233 (57%)
Female, n (%) 176 (43%)
Mean (SD) age, years 67.3 (10.0)
Mean (SD) BMI, kg/m2 26.2 (5.2)
Current smokers, n (%) 156 (39%)
Mean (SD) smoking pack years 44.1 (27.8)
Mean (SD) FEV1, % of predicted 55.5 (16.6)
Mean (SD) FEV1, liters 1.5 (0.6)
mMRC dyspnea scale
0–1, n (%) 226 (55%)
≥2, n (%) 183 (45%)
Exacerbations in the previous year
None, n (%) 273 (67%)
≥1, n (%) 136 (33%)
Types of physical activity
Walking, n (%) 360 (88%)
General bicycling, n (%) 102 (25%)
Gardening, n (%) 124 (30%)
Sports, n (%) 172 (42%)
Light household activities, n (%) 367 (90%)
Heavy household activities, n (%) 238 (58%)
BMI body mass index, FEV1 forced expiratory volume in 1 s,mMRCModiﬁed
British Medical Research Council, SD standard deviation
Table 2. Prevalence of comorbidities at study baseline (N= 409)
Comorbidity n (%)
Cardiovascular diseases 149 (36%)
Symptomatic heart diseases (coronary heart diseases or
myocardial infarction or angina pectoris or heart failure)
80 (20%)
Other cardiovascular diseases 97 (24%)
Neurological disorders 59 (14%)
Cerebrovascular accident 37 (9%)
Other neurological disorders 28 (7%)
Endocrine disorders 97 (24%)
Diabetes mellitus 63 (15%)
Other endocrine disorders 46 (11%)
Musculoskeletal disorders 146 (36%)
Rheumatoid arthritis 15 (4%)
Arthrosis 51 (12%)
Other musculoskeletal disorders 112 (27%)
Mental disorders (anxiety or depression) 66 (16%)
Anxiety 44 (11%)
Depression 41 (10%)
Cancers 58 (14%)
Infectious diseases 20 (5%)
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risk factors for comorbidities, such as physical inactivity, would
thus be extremely important.
A primary strength of this analysis is the use of data from a
prospective cohort study. Previous research was heavily based on
prevalent cases of comorbidities so there was a high likelihood
that lower levels of PA were in fact a result of comorbidities. For
example, a recent prospective study showed that depression
symptoms are associated with reduced PA measured 6 months
later in patients with COPD.17 Our longitudinal study design
permitted us, ﬁrstly, to clarify the temporal relationship between
PA and comorbidities. Secondly, we captured the incident cases of
comorbidities owing to the prospective follow-up design. Thirdly,
with mortality data, we can conduct thorough analysis that
accounted for death as a competing risk against comorbidities.
Although we did not observe a statistically signiﬁcant association
for most comorbidities examined, the ﬁndings suggest, in both
unadjusted and adjusted analyses, that higher PA levels may be
associated with a lower risk of most comorbidities.
There may be misclassiﬁcation of our exposure and outcome. In
particular, our assessment of PA was performed by patient self-
report, which is prone to recall and response bias18 and may
under- or over-estimate PA. Furthermore, the comorbidities were
assessed based on patients’ self-report every half-year, instead of
more objective physiological measurements or clinician’s diag-
nosis. It is difﬁcult to assess the net impact of these various
sources of potential misclassiﬁcations on our ﬁndings. Given that
substantial epidemiological evidence has suggested the health
beneﬁts of PA for preventing chronic diseases in general
population and subpopulations,19, 20 we believe, on the whole,
attenuation of a protective effect of PA against developing
comorbidities would be most likely. Often, non-differential
misclassiﬁcation of exposures or outcomes will attenuate the true
association, which is probably the case here.
We aggregated some comorbidities (e.g., coronary heart
diseases, myocardial infarction, etc. into cardiovascular diseases)
to avoid potential diagnostic overlap and to increase statistical
power. This aggregation, however, implies that we assumed
identical pathophysiologic mechanisms underlying the role of
physical inactivity in causing the various diseases within a cluster.
Such an assumption may be reasonable since studies have shown
that PA improves many physiological measures such as for
cardiorespiratory and muscular ﬁtness, bone health, and cogni-
tive function.19, 20 In a recent pooled analysis of 1.44 million
participants from cohort studies,21 higher levels of leisure-time PA
were even found to be associated with lower incidences of 13
types of cancer. We do not know to what extent our aggregation
of outcomes impaired the study validity. Studies that examine the
beneﬁts of PA in each type of chronic disease are needed in order
to test the assumptions we made.
Another weakness of the study includes that our study sample
did not include COPD patients at the early stage (i.e., Global
Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1),
while it has been shown that reduced PA is a critical feature of
these patients.22 Our assessment of patients’ PA was at more
advanced stages of the disease, so we may not have captured
the exposure (PA levels) at the most relevant time points,
assuming that early decrease in PA is important to the
development of comorbidities. Finally, we modeled PA levels
as a continuous variable. It is likely that the associations
between PA and risk of some comorbidities are not linear (on
logit scale) or a threshold value of PA exists; however, to test for
this, a much larger sample size (number of events in survival
analysis) is needed.
Fig. 1 Distribution of patients with 0 or 1 category of comorbidities, ≥2 categories of comorbidities, and patients who were dead or lost to
follow-up over time (n= 409). Seven categories of comorbidities were included. At each visit, we recorded if the patients had been diagnosed
with cardiovascular diseases, neurological disorders, endocrine disorders, musculoskeletal disorders, and cancers and we also recorded if the
patients had ever reported having infections and mental disorders (anxiety or depression) after being enrolled in the study. Over time,
patients in the groups “0 or 1 comorbidity” or “≥2 comorbidities” can move to the group “death” or “loss to follow-up”. Also, patients in the
group “0 or 1 comorbidity” can move to the group “≥2 comorbidities”
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Implications
Mental disorders are more common in patients with COPD than in
the general population,23 and depression and anxiety have been
shown to increase the risk of COPD exacerbations, and possibly
death.23 Searching for effective interventions to cope with
depression and anxiety is thereby of great importance to clinicians
who manage COPD patients. The negative association between PA
and depression or anxiety in the general population has been
widely suggested in previous research, such as in the National
Comorbidity Survey in the United States.24 Our study showed that
this may also apply to COPD as we found more physically active
patients (with higher PA levels equivalent to 2.5 metabolic
equivalent tasks (METs), e.g., those who report walking outside
vs. those who do not) had 15% and 11% lower risks of developing
depression and anxiety, respectively, compared to physically
inactive patients. Most existing pulmonary rehabilitation programs
for COPD patients comprise exercise as the main component.
There is trial evidence that suggests pulmonary rehabilitation
reduces symptoms of existing depression and anxiety25 but it is
unclear if such interventions also lower the risk of incident
depression and anxiety. In the future, it would be helpful for
patients to have strategies to increase and maintain exercise
capacity and PA beyond rehabilitation programs by using a wide
range of interventions targeted at individuals or community in
patient’s daily life.
MATERIALS AND METHODS
Subjects
The current study included 409 patients with COPD from the International
collaborative effort on chronic obstructive lung disease: exacerbation risk
index cohorts (ICE COLD ERIC) study.14, 15 Patients with GOLD stage 2–4
who were aged≥ 40 years, who had been free of exacerbations for
≥4 weeks were recruited in the Netherlands and Switzerland between
2008 and 2009. Patients considered having ≤ 12 months of life expectancy
and having serious mental disorders were excluded. All patients provided
their informed consent and the study was approved by the corresponding
ethics boards.
Assessment of PA
We used the LAPAQ to assess patients’ PA levels.26 At baseline, patients
were asked to indicate the frequency and duration of six types of PA they
had performed during the previous 2 weeks. A LAPAQ score that integrates
the time spent on each PA (minutes per day in the previous 2 weeks) and
the intensity of each PA, informed by the METs,27 can be generated.
However, and as described previously,28 we constructed a new LAPAQ
score omitting information on frequency and duration, where we found
missing or implausible values. We used patients’ responses to the types of
PA only and assigned weights to each PA according to the METs: 2.5 for
outside walking, 4.0 for bicycling, 4.0 for gardening, 6.0 for sports, 2.5 for
light household activities and 4.0 for heavy household activities. Thus, the
new LAPAQ score is on a scale from 0 to 23. It was found highly predictive
for mortality and the reliability of the new score was moderate to good.28
More details on the new LAPAQ score can be found in the e-Appendix.
Assessment of outcomes
Experienced and trained study physicians or nurses assessed patients’
prevalent comorbidities at the baseline interview. First, patients completed
open-ended questions regarding their comorbidities. Then, experienced
and trained study personnel compared the comorbidities reported by
patients with their list of medications (in Switzerland also their medical
charts). Mismatches between patients’ responses and their list of
medications (or charts) were resolved by clariﬁcation with patients’
general practitioners. Depression and anxiety were measured using the
Hospital Anxiety and Depression Scale questionnaire. We considered
patients to have clinically relevant levels of anxiety or depression if their
score was 11 points or higher to ensure the “caseness” for depression and
anxiety.29 Incident comorbidity proﬁles were updated every 6 months via
postal questionnaires/phone interviews and face to face contacts (at two
and 4 years of follow-up). We then created categories of these
comorbidities.
Fig. 2 Associations of physical activity with incident comorbidities. The relative-risk ratios estimated from multinomial logistic regression
models (competing risk model) were interpreted as hazard ratios. Age, sex, body mass index, smoking pack-years, and forced expiratory
volume in 1 s (liters) were included as covariates in the model
Physical activity and comorbidities in COPD
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Statistical analysis
We performed multinomial logistic regression (STATA, version 13.1, College
Station, TX, USA) as a close approximation to competing risk discrete time
proportional hazards model to assess the association of PA with incidence
of comorbidity while treating death (a competing event) as a separate
category.30, 31 We chose this model instead of other survival models
because comorbidity data were updated at 6-monthly occasions. Firstly,
we examined the risk of developing a new (or an additional) comorbidity
in all patients. Then, we examined the risk of developing each category of
comorbidity separately. We identiﬁed the subjects who were free of the
comorbidity at baseline and who had at least one additional follow-up
visit. We deﬁned survival time as the time to the ﬁrst visit on which the
occurrence of the comorbidity was identiﬁed. If no occurrence of
comorbidity was identiﬁed, survival time was deﬁned as the time to the
last follow-up visit or, for those who died during study period, the time to
the visit where the patient was reported dead. The relative-risk ratios
estimated from multinomial logistic regression models were interpreted as
hazard ratios. An example of how we implemented this model is provided
in the e-Appendix.
We adjusted for potential confounders in the multivariable analyses,
which included age, sex, body mass index (BMI), smoking pack-years, and
forced expiratory volume in one second in liters (FEV1). Because that the
induction time between exposure (PA) and outcomes (development of
comorbidities) may be years or decades and that PA may already be
inﬂuenced by some comorbidities before comorbidities are reported, we
decided to use the baseline LAPAQ scores to assure the temporal
relationship to comorbidities. We did sensitivity analyses using average of
the values over time (from baseline to the last visit before the patient had
the event or was censored) for PA and two covariates (BMI and FEV1), for
which we had multiple assessments in our cohort. We recoded the
independent variable LAPAQ score by dividing the score by 2.5 (the MET
for walking outside) to aid interpretation of the hazard ratios, which
estimate the increase in the risks for a 2.5-point increase in the LAPAQ
score.
CONCLUSIONS
Our investigation of the association of PA with comorbidity in COPD
highlighted that patients with high levels of PA may be less likely to
develop depression or anxiety over time. We observed modest, but
plausible associations of PA with comorbidities such as cardiovascular,
endocrine, musculoskeletal, malignant, and infectious diseases, while low
numbers of incident morbidity yielded wide CIs. The results of our study
imply that rehabilitation and PA promotion programs may not only be
important to increase exercise capacity and levels of PA but also can be an
approach for testing to lower the risk for incident depression and anxiety
in patients with COPD.
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